RxDoctor Payments Data

Anthony Lombardi, MD

Internal Medicine · Warwick, RINPI 1154372472

Payments from drug & device makers

$627in general payments, 2019–2025

Across 12 payments — averaging $52.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$237
  • Johnson & Johnson$146
  • Takeda Pharmaceuticals U.S.A., Inc.$125
  • Exact Sciences$36
  • Abbott$30
  • Pfizer$29
  • plus $25 from 1 others

What the payments were for

  • Food & beverage$627100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$627 in reported general payments places this provider in the 75th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$58,392
Medicare patients
185
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$110,046
JardianceEmpagliflozin95$65,493
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$51,713
JanuviaSitagliptin Phosphate51$50,447
OxycontinOxycodone Hcl67$44,368
XareltoRivaroxaban41$44,327
OzempicSemaglutide30$27,154
Breo ElliptaFluticasone/Vilanterol20$14,392
Spiriva RespimatTiotropium Bromide19$9,331
Atorvastatin Calcium611$9,121
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$5,834
MyrbetriqMirabegron25$5,734
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen221$5,298
Metoprolol Succinate263$4,727
Tresiba Flextouch U-100Insulin Degludec11$4,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$110,046210 claims
Johnson & JohnsonXarelto$146$44,32741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →